Improvement of diseases related to the digestive system: for example, against inflammation in cases of gastritis, gastric ulcer, pancreatitis, intestinal inflammation , and Crohn's disease
A meta-analysis revealed that for each kilogram of weight loss, patients typically experience at least a 1 mmHg reduction in blood pressure [4]
For patients who require glucocorticoid dose reduction or cannot tolerate standard therapy due to side effects, GLPS, particularly CG, can serve as an adjunctive or alternative treatment option to help control the disease and reduce glucocorticoid-related adverse effects ( The concanavalin A (ConA)-induced liver injury model is commonly used to study AIH
Yes, through the personalized-dosing route for compounded tirzepatide where a medical need is documented, plus brand tirzepatide access (Mounjaro and Zepbound)